With its new cGMP facility in Zurich, Siegfried subsidiary Dinamiqs has reached an important milestone in the manufacture of viral vectors. The company combines research, development, and clinical and commercial production under one roof, thereby significantly expanding its capacities. At the same time, Dinamiqs is entering into a collaboration with Seal Therapeutics to advance the development of...